Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Correction that 46 million was for OPLI (actually closer to 47). For CANFY it looks like the ADRS are a 50-1 ratio and there are 273,379,902 shares listed on the TASI which would mean about 5.5 million in CANFY equivalent. I would wait till someone more familiar posts something as I'm still looking at them and could have easily missed/misinterpreted something!
OK I see they have 46 million shares outstanding (shouldn't trust yahoo) so the market cap is in the ~225million US neighborhood. At first I saw they owned 82% of OPLI and saw their market cap and thought it really odd.
Seems like an interesting company/speculation. Is the market cap really ~16 million US?
It would seem to fit mcbio's speculative criteria .
On a more serious note how do you think their Psoriasis drug would stack up with Fumarate or if XNPT develops their "better" BG-12?
I'll start looking at them but as you know always looking for someone to save me some work TIA
Can-Fite (TASE:CFBI; OTC:CANFY)
CF101 Psoriasis Phase II/III quantitative interim results, see slide 12 in the presentation:
http://www.canfite.co.il/upload/2012-12-30_Can-Fite_Overview-English_isa.pdf
Not stat-sig vs placebo at 12 weeks with data from 103 patients, but with additional 188 patients I think it will be.
One odd observation: placebo switchers improved as soon as being put on the 2 mg drug (too quickly) after week 12.
The PR:
http://www.canfite.co.il/upload/2012-12-30%20Psoriasis%20additional%20analysis%20-%20English.pdf
Less than 5% price increase ain't a
big deal ..... yet.
Here is to the next Viagra!!!
Bravo Pnina!!!
Pnina Fishman makes it big #msg-81444268
You were clear, please be even clearer!
Do you like the companys' prospects?
Just to be clear, what I meant to say was that the faster track to market story shouldn't be the main reason to like PSTI.
Indeed, that was it.
Too many ifs i suppose!
Well, i'll have to look at
other possibilities.
Thanks Dt
I assume this piece triggered your question:
http://www.globes.co.il/serveen/globes/docview.asp?did=1000791112&fid=1725
Of course, a faster and cheaper clinical path would be good for any drug developing company, but note that Dr. Hamburg said the agency is considering a faster track for drugs with "special medical use" label. Don't know when a guideline will be issued and if one of PSTI's treatments qualifies at all.
Hi DT
Your opinion of PSTI? You think
FDA quick track clearance grant
for humanitarian reasons treatments
(expected soon, or so i gather)
might give the company a quick boost?
TIA
I remember you liked her. Hopefully it means
you like the companys prospects too
As for separate boards for specific companies
it makes sense in general, alas Israeli stocks
have no audience or hardly any at all!
Why do i do it? habit i guess, like many others
i created over the years!
Good night, see you around!!!
Why a separate board?
I know and respect Pnina Fishman, fwiw.
If it were up to Humi he would never sell under $30 but the guys upstairs, i don't trust them.
BTW i invested some in CANFY #board-25711
although small change in comparison to GIVN
Lunch, dinner and breakfast too!!!
I knew IDB needed cash, but i did believe
that the GIVNs value for a company like
Fuji is $ 24, and if IDB had more 'patience'
it could fetch $30 easily!!!
I was thinking of you earlier #msg-80655599
Don't know about your price target, $24 might be too high. If you bought in Aug at high $12 why not sell now?
GIVN going places! Dankner needs the dough,
although mere peanuts to his huge party fiasco
debts!!!
$24, here we come!
If you believe there's a good chance for PillCamColon 2 to be approved by the FDA next year, then definitely yes. They made good impression on me and as far as my not-so-good technical understanding goes, improvements made in the 2nd gen pill should allow it to pass the FDA bar.
Dream shattered!!!
Cool and breathtaking - The Pyrenees.
Thanks Genisi, enjoy your vacation! Hope for you it's
in a cooler spot than TLV !!!
Sorry for the belayed reply (I'm on vacation). If you want my view on GIVN, just follow the thread Roy started in #msg-72256508.
A question, a statement and some wishful thinking too
My guestimate, based on above is that GIVN will meet
pps of above 20$ before year end!
This, Roy, is by no means a buy recommendation!
On a more serious note, Genisi, your learned
opinion about GIVN? Rumours about buyout, good
news expected in regards news to be released Q4?
Compassionate Patient Interview on Israeli Channel 2 TV with English Captions, for Brainstorm Cell Therapeutics English Speak...
#msg-77232588
Thanks Genisi.... it's a gamble all right,
i am into deep green, and volume makes it
possible to escape any day! (almost)
BCLI is the real deal and the testimonials keep trickling out. However the stock is a lottery ticket with many unknowns. I bought some gamble shares at .30. We should get some info on the other patients shortly.
http://israel21c.org/health/israeli-clinical-study-offers-hope-to-als-patients/
http://www.globes.co.il/serveen/globes/docview.asp?did=1000670741&fid=1725
http://alsn.mda.org/news/safety-efficacy-in-brainstorm-stem-cell-trial
Dovi, hope you bought before that story posted in #msg-77202032. If so, take the money out. Otherwise, trust in god, this strategy worked well for the Rabbi (#msg-77207916).
Hi Genisi
What is your learned opinion about BCLI?
I threw in some monies i managed to scrap.
Rgds
Dubi
Join here for more Low Float penny
http://investorshub.advfn.com/Penny-$$-Tiny-Float-*-Low(OS-&-AS)-24974/
They could probably use this in Israel as well http://investorshub.advfn.com/boards/read_msg.aspx?message_id=76023792
DiaPep277 got Orphan Drug Product Designations from the FDA. As the molecule has been around forever I assume patents are very old, so at least they'll have 7 years exclusivity if approved.
http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=337111
They were under the radar until today and I don't know much beyond what's in their web
http://www.juvenisbiomed.com/tech.asp
ELOS invests in biopolymer filler from Juvenis:
#msg-73472980
Comments?
End of story for D-Pharm's DP-b99 #msg-71233181
BiolineRx announced today the commencement of the PRESERVATION I clinical trial
http://finance.yahoo.com/news/BioLineRx-Announces-bw-2985022359.html?x=0
Andromeda/Teva/Clal DiaPep277 in type I diabetes
The first phase III trial met its primary and secondary endpoints, and was found to be effective and safe.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000699926&fid=1725
Andromeda/Teva/Clal DiaPep277
Data from the first phase III trial are expected next month. A free full text review on the area:
http://www.discoverymedicine.com/Dequina-Nicholas/2011/04/07/autoantigen-based-vaccines-for-type-1-diabetes/
Cypress Bioscience/Royalty Pharma ditched CYP-1020.
Ikaria will start pivotal trial with IK-5001 (a.k.a. BL-1040 from BioLineRx) in mid 2011.
http://www.clinicaltrials.gov/ct2/show/NCT01226563?term=IK-5001&rank=1
Kamada is going to start a phase I/II safety and preliminary efficacy clinical trial of its IV Alpha-1 Antitrypsin (AAT) in type 1 diabetes. A couple of more recent basic research works in the area:
http://www.ncbi.nlm.nih.gov/pubmed/21099312
http://www.ncbi.nlm.nih.gov/pubmed/20692406
Baxter's Aralast is being tested by the NIAID for that indication: (looks like the trial is still in its first part (safety))
http://clinicaltrials.gov/ct2/show/NCT01183468
There is one commercial company trying to pursue the area:
http://www.omnibiopharma.com/development
Dew, I have to go back and look!
What was the name of the product? T.i.a.
Followers
|
14
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1367
|
Created
|
09/23/05
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |